Overview
Prilenia is a biopharmaceutical company focused on developing neuroprotective therapies targeting the sigma-1 receptor for neurodegenerative and neuropsychiatric diseases. The company combines drug development expertise with global operations to advance disease-modifying treatments and ensure patient access to innovative neurological therapies.
More in Neurotechnology
Latest industry news
Precision Neuroscience Raises $250M to Accelerate Brain-Computer Interface Development
2026-11-01 · Funding
Merge Labs Gets Competition as New Rival Neurotech Startup Enters the Consumer BCI Arena
2026-10-31 · Industry
Neuralink Connects to Grok AI Agent, Enabling ALS Patient to Control AI and Make Calls by Thought Alone
2026-10-30 · Product
Implanted BCIs Still Lack a Shared Safety Rulebook, and the Field Is Running Out of Time to Write One
2026-10-29 · Research
Company details
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →